XLRN News and Press, Acceleron Pharma Inc. From 04/05/21

– Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patients – – Interim results from the SPECTRA Phase 2 trial to show i...

– Results show patients treated with sotatercept experienced improvements in hemodynamic and functional endpoints compared with placebo – – Sotatercept was generally well tolerated; adverse events were consistent with previously published data on sotaterce...

Editas Medicine (EDIT) is trading ~3.8% higher in pre-market hours after Credit Suisse initiated coverage with an outperform rating. The price target of $58.00 per share indicates an upside of ~28.9% to the previous close.Analyst Tiago Fauth argues that the company is a pioneer in CRISPR...

Citi analyst Yigal Nochomovitz is reiterating his buy rating on shares of Acceleron Pharmaceutical Inc. (XLRN) shares and increasing his price target from $137 to $171.Nochomovitz says his bullishness on shares is backed by the strong launch of anemia therapy Reblozyl with partner Bristol Mye...

Image source: The Motley Fool. Acceleron Pharma Inc (NASDAQ: XLRN) Q4 2020 Earnings Call Feb 25, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Acceleron Pharma Inc (XLRN) Q4 2020 Earnings Call Transcript

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Acceleron Pharma Inc. 2020 Q4 - Results - Earnings Call Presentation

Acceleron Pharma Inc. (XLRN) Q4 2020 Results Conference Call February 25, 2021 05:00 PM ET Company Participants Jamie Bernard - Director of Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Jay Backstrom - Head of Research and Development Suja...

Acceleron Pharma (XLRN): Q4 GAAP EPS of -$0.95 misses by $0.38.Revenue of $25.87M (-34.2% Y/Y) misses by $6.44M.Cash, cash equivalents and investments as of December 31, 2020 were $857.5 million.Press Release For further details see: Acceleron Pharma EPS misses by $0.38, misses on reven...

- Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions - - STELLAR Phase 3 trial initiated with sotatercept in PAH - ...

Acceleron Pharma (NASDAQ:XLRN) is scheduled to announce Q4 earnings results on Thursday, February 25th, after market close.The consensus EPS Estimate is -$0.55 (vs. $-0.44 in year ago quarter) and the consensus Revenue Estimate is $32.31M (-17.9% Y/Y).Over the last 2 years, XLRN has beat...